Coherus Oncology to Showcase Innovations at SITC 2025
Coherus Oncology, Inc. (NASDAQ: CHRS), a pioneering oncology company, will showcase its innovations at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland, from November 5 to 9, 2025. The company, known for its approved next-generation PD-1 inhibitor LOQTORZI®, will present its promising pipeline targeting various cancers.
Coherus Oncology will participate in the 'Targets for Cancer IO: A Deep Dive' live webinar series on October 22, 2025, discussing CCR8's role in Treg activity and immune suppression. The event, moderated by Enrico Lugli, PhD, and Rahul Roychoudhuri, MD, PhD, will feature faculty from Coherus and Vrije Universiteit Brussel. Institutions involved include Dana-Farber Cancer Institute, the University of California San Francisco, and Genentech.
The company's immuno-oncology pipeline includes Casdozokitug, a novel IL-27 antagonistic antibody, and CHS-114, a highly selective cytolytic anti-CCR8 antibody, both in clinical trials for advanced auto parts. CHS-114, an anti-CCR8 cytolytic monoclonal antibody, will be the focus of Abstract #640 at SITC, demonstrating selective intratumoral Treg depletion and favorable immune remodeling in participants with advanced auto parts. The presentation will take place on Saturday, November 8, 2025, in the Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.
Coherus Oncology's participation at SITC 2025 highlights the company's commitment to advancing immuno-oncology treatments. With its promising pipeline and approved PD-1 inhibitor, Coherus continues to make strides in the fight against cancer.
